Callerio Foundation



LINFA originates from the experience cumulated in the course of studies on the most important pharmacological properties of a new ruthenium-based antimetastasis drug.

LINFA poses itself as a reference point for research on the antimetastasis properties of new complexes being identified within scientific institutions for basic research on the subject. LINFA
LINFA has the main goal of promoting studies on the pharmacological treatment by means of ruthenium-based drugs of metastases released by solid tumours.

Changes of activity

In the initial stages of working in LINFA all the compounds proposed were tested, without any discussion on the nature of the chemical characteristics of the compounds themselves. However, the goal of getting selective compounds for treating solid tumour metastases would have needed the definition of specific targets.
Selectivity is certainly not achieved through the capacity of some metal-based complexes to bind bases (i.e. guanine) or to bend DNA on the minor or major groove. On the contrary, selectivity might result from the research that biologists, geneticists, molecular and structural chemists, and pharmacologists have done to highlight the relevance of the fine mechanisms that regulate cancer growth and metastasis formation, suggesting new selective targets for cancer chemotherapy.
LINFA wants to adhere to these new knowledges and wants to address the chemistry of metal-based compounds to explore these new targets.
Therefore, no more testing of "unspecific" compounds but the choice of targeted compounds aimed at inhibiting metastasis growth through the modulation of the metastatic physiological signals that keep metastases alive.

Organization of experimental testing